Singapore, Feb. 16 -- Singapore-based iX Biopharma has been awarded a $40.95 million development contract by the United States Government to fund the development of Wafermine(R), its patented sublingual ketamine wafer for the treatment of acute moderate to severe pain.

Published by HT Digital Content Services with permission from BioSpectrum Asia....